Shares in one of China’s largest biotech companies fell nearly 10 per cent in Hong Kong on Friday after a report accused it of inflating sales data and overstating research costs. BeiGene said in a statement to the Hong Kong exchange that the report was “based on unfounded and misleading allegations”, adding that it “has always adhered to standards of compliance, ethics and integrity”.
blaineonline.finance.blog 